Loading...
•
Jun 30
Roivant Sciences Q1 2025 Earnings Report
Roivant Sciences reported financial results for Q1 2025 and provided a business update.
Key Takeaways
Roivant Sciences reported a net income of $57.5 million for the quarter ended June 30, 2024, compared to a net loss of $327.8 million for the same period in 2023. VTAMA net product revenue was $18.4 million. The company's consolidated cash, cash equivalents, and restricted cash stood at $5.7 billion as of June 30, 2024.
Immunovant completed enrollment in batoclimab pivotal myasthenia gravis (MG) trial.
Brepocitinib development in non-infectious uveitis (NIU) is progressing to Phase 3.
VTAMA net product revenue was $18.4M for the first quarter ended June 30, 2024.
Roivant reported its consolidated cash, cash equivalents and restricted cash of $5.7B at June 30, 2024.
Roivant Sciences
Roivant Sciences
Forward Guidance
Roivant anticipates several milestones in the coming quarters, including PDUFA action for VTAMA in atopic dermatitis in Q4 2024, topline data from the Phase 2 trial of namilumab for sarcoidosis in Q4 2024, and initiation of a Phase 3 program for brepocitinib in NIU in the second half of 2024.
Positive Outlook
- Dermavant expects PDUFA action for VTAMA in atopic dermatitis in the fourth quarter of calendar year 2024.
- Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the fourth quarter of calendar year 2024.
- Priovant plans to report topline data from the ongoing Phase 3 trial of brepocitinib in DM in the second half of calendar year 2025 and to initiate a Phase 3 program for brepocitinib in NIU in the second half of calendar year 2024.
- Immunovant plans to have initiated 4-5 potentially registrational programs by March 31, 2025, and plans to have initiated studies in a total of 10 indications by March 31, 2026, for IMVT-1402.
- Immunovant expects to have at least 3 IND applications active by the end of calendar year 2024.